Numerous families carrying APP, PSEN1, or PSEN2 mutations have been studied collectively to determine the time course of fluid biomarker, neuroimaging, and clinical changes prior to the expected onset of AD symptoms, which is based on the age of symptom onset in a parent with the same mutation. The gene discussed is PSEN1; the disease is Alzheimer disease.